Active, not recruitingPHASE2, PHASE3NCT06907290
A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection
Studying Hepatitis delta
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Intervention
- Brelovitug 300 mg(drug)
- Enrollment
- 150 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2029
Study locations (30)
- 247 Garden Grove, Garden Grove, California, United States
- 242 Huntington Beach, Huntington Beach, California, United States
- 252 Long Beach, Long Beach, California, United States
- 244 Los Angeles, Los Angeles, California, United States
- 250 Miami, Miami, Florida, United States
- 251, Illinois, Chicago, Illinois, United States
- 248 Lowa, Cities in Iowa, Iowa, United States
- 254 Baltimore, Baltimore, Maryland, United States
- 241, Massachusetts, Boston, Massachusetts, United States
- 245 New York, New York, New York, United States
- 256 New York, New York, New York, United States
- 253 New York, New York, New York, United States
- 255 New York, New York, New York, United States
- 257 Philadelphia, Philadelphia, Pennsylvania, United States
- 249 San Antonio, San Antonio, Texas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06907290 on ClinicalTrials.govOther trials for Hepatitis delta
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT07454837Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving BulevirtideMirum Pharmaceuticals, Inc.
- RECRUITINGNCT07491848Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+DResearch Center of Periodontal-Systemic Interactions
- RECRUITINGPHASE3NCT07298330A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)Mirum Pharmaceuticals, Inc.
- RECRUITINGNCT07317011"Referral Attivo" Delta, Dallo Screening Alla Presa in Carico.FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- RECRUITINGNCT07429864Changes in Bile Acids and Microbiota in Patients With Hepatitis D Treated With BulvertideFondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGPHASE3NCT07200908A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)Mirum Pharmaceuticals, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT07142811A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV InfectionVir Biotechnology, Inc.
- RECRUITINGPHASE1, PHASE2NCT07096193Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta VirusGilead Sciences